NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Price, News & Analysis $1.96 +0.21 (+12.00%) Closing price 04:00 PM EasternExtended Trading$1.85 -0.11 (-5.61%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Regulus Therapeutics Stock (NASDAQ:RGLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Regulus Therapeutics alerts:Sign Up Key Stats Today's Range$1.67▼$2.0150-Day Range$0.97▼$1.7552-Week Range$0.83▼$2.90Volume1.27 million shsAverage Volume656,982 shsMarket Capitalization$129.84 millionP/E RatioN/ADividend YieldN/APrice Target$12.75Consensus RatingBuy Company OverviewRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More… Remove Ads Regulus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreRGLS MarketRank™: Regulus Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 388th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRegulus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRegulus Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Regulus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regulus Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.84% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Regulus Therapeutics has recently decreased by 8.93%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.84% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Regulus Therapeutics has recently decreased by 8.93%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.64 News SentimentRegulus Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Regulus Therapeutics this week, compared to 2 articles on an average week.Search Interest14 people have searched for RGLS on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.MarketBeat Follows3 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have sold 274.88% more of their company's stock than they have bought. Specifically, they have bought $75,287.00 in company stock and sold $282,237.00 in company stock.Percentage Held by InsidersOnly 4.35% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regulus Therapeutics' insider trading history. Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RGLS Stock News HeadlinesRegulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech SummitApril 2 at 8:00 AM | prnewswire.comRegulus Therapeutics Leads The Charge Among 3 Promising Penny StocksMarch 31 at 5:35 PM | uk.finance.yahoo.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)Regulus upgraded to Overweight from Equal Weight at Wells FargoMarch 29, 2025 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)March 29, 2025 | markets.businessinsider.comRegulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by Wells Fargo & CompanyMarch 29, 2025 | americanbankingnews.comRegulus jumps after data update from early-stage trial for kidney disease therapyMarch 28, 2025 | msn.comWells Fargo Upgrades Regulus Therapeutics (RGLS)March 28, 2025 | msn.comSee More Headlines RGLS Stock Analysis - Frequently Asked Questions How have RGLS shares performed this year? Regulus Therapeutics' stock was trading at $1.58 at the start of the year. Since then, RGLS stock has increased by 24.1% and is now trading at $1.96. View the best growth stocks for 2025 here. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its earnings results on Thursday, March, 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.20). When did Regulus Therapeutics' stock split? Regulus Therapeutics's stock reverse split on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY). Company Calendar Last Earnings3/20/2025Today4/02/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RGLS CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$12.75 High Stock Price Target$28.00 Low Stock Price Target$6.00 Potential Upside/Downside+550.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.07% Return on Assets-48.58% Debt Debt-to-Equity RatioN/A Current Ratio14.15 Quick Ratio14.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.87Miscellaneous Outstanding Shares66,243,000Free Float62,651,000Market Cap$129.84 million OptionableOptionable Beta1.42 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:RGLS) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.